FDA Approves Expanded Use Of Johnson & Johnson's TRUFILL N-BCA For Subdural Hematoma
(RTTNews) - Johnson & Johnson MedTech, the medical technology arm of Johnson & Johnson (J&J) on Thursday said the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its TRUFILL n-BCA Liquid Embolic System. The device is now cleared for embolization of the middle meningeal artery (MMA) as an adjunct to surgery in the treatment of symptomatic subacute and chronic subdural hematoma (cSDH).
The approval is supported by the MEMBRANE study, which evaluated the safety and effectiveness of MMA embolization in patients with cSDH. The study found that TRUFILL n-BCA was more effective than standard of care for MMA embolization in treating symptomatic cSDH, while demonstrating a favorable safety profile.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.